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Abstract: Injection drug use (IDU) continues to be a significant public health issue in the 
U.S. and internationally, and there is evidence to suggest that the burden of injection drug 
use  and  associated  morbidity  and  mortality  falls  disproportionately  on  minority 
communities. IDU is responsible for a significant portion of new and existing HIV/AIDS 
cases in many parts of the world. In the U.S., the prevalence of HIV and hepatitis C virus is 
higher among populations of African-American and Latino injection drug users (IDUs) than 
among  white  IDUs.  Methadone  maintenance  therapy  (MMT)  has  been  demonstrated  to 
effectively reduce opiate use, HIV risk behaviors and transmission, general mortality and 
criminal  behavior,  but  opiate-dependent  minorities  are  less  likely  to  access  MMT  than 
whites. A better understanding of the obstacles minority IDUs face accessing treatment is 
needed to engage racial and ethnic disparities in IDU as well as drug-related morbidity and 
mortality.  In  this  study,  we  explore  knowledge,  attitudes  and  beliefs  about  methadone 
among  53  out-of-treatment  Latino  and  African-American  IDUs  in  Providence,  RI.  Our 
findings suggest that negative perceptions of methadone persist among racial and ethnic 
minority IDUs in Providence, including beliefs that methadone is detrimental to health and 
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that  people  should  attempt  to  discontinue  methadone  treatment.  Additional  potential 
obstacles to entering methadone therapy include cost and the difficulty of regularly attending 
a methadone clinic as well as the belief that an individual on MMT is not abstinent from 
drugs.  Substance  use  researchers  and  treatment  professionals  should  engage  minority 
communities, particularly Latino communities, in order to better understand the treatment 
needs  of a diverse population,  develop  culturally appropriate MMT programs, and raise 
awareness of the benefits of MMT. 
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1. Introduction 
 
Injection  drug  use  (IDU)  continues  to  be  a  significant  public  health  issue  in  the  U.S.  and 
internationally, and there is evidence to suggest that the burden of injection drug use and associated 
morbidity and mortality falls disproportionately on minority communities. In 96 of the largest U.S. 
metropolitan areas, the median prevalence of injection drug users in 2002 was estimated to be 96.1 per 
10,000  people,  with  a  great  deal  of  variation  in  different  metropolitan  areas  [1].  Though  recent 
estimates suggest that black-white disparities in IDU have declined, IDU is still more prevalent among 
blacks, with white IDU prevalence in 2002 at approximately 90 per 10,000 adults and black IDU 
prevalence at 156 per 10,000 adults [2,3]. On average, rates of IDU are similar in Hispanic and non-
Hispanic white populations, but disparities in IDU are present in some metropolitan areas [2], and the 
collection of data on Hispanics as a whole may obscure the significant variability between Hispanic 
subgroups [4,5]. U.S.-born Hispanics report higher rates of substance use than immigrants [6], and 
among Hispanics diagnosed with AIDS, those born in the U.S.A. or Puerto Rico were more likely to 
have contracted HIV through IDU than those born in Central or South America, Mexico, or Cuba [7]. 
Metropolitan areas with greater white-Latino differences in IDU tend to be located in the Northeast, an 
area  where  the  majority  of Latinos  are of Puerto Rican origin  [2]. In the Northeast,  Latino-white 
disparities in IDU may be due to the relatively high rates of heroin use and high levels of residential 
segregation, which has been linked to increased IDU, found among Puerto Ricans living in mainland 
US [2,5,8]. 
Among injection drug users (IDUs), average HIV prevalence in the 96 largest U.S. metropolitan 
areas has been estimated to be 6.2% [9], far greater than the prevalence in the general population [10]. 
More than one in  five people become infected with  hepatitis  C virus (HCV) within two years of 
beginning injection drug  use, and more than one in three become infected within five years  [11]. 
Hispanic IDUs are significantly more likely to be infected with HCV than non-Hispanic white or black 
IDUs [11,12]. Studies have shown also that HIV prevalence is higher among black and Latino IDUs 
than among white IDUs [13,14]. In addition to infectious disease risk, minorities are also at higher risk 
of dying from an overdose [15].  
Racial and ethnic minorities bear a disproportionate share of drug-related morbidity and mortality, 
yet, as with other medical conditions in the U.S., they are less likely to receive the treatment services Int. J. Environ. Res. Public Health 2009, 6                 
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they need [16-18]. The drug treatment needs of different racial and ethnics groups vary significantly, as 
do the effects of treatment and ancillary social and health services [16]. African Americans and Latinos 
are less likely to receive services matched to their specific needs and are generally underserved by 
substance use treatment programs [16,19]. Data from a U.S. national survey indicates that a higher 
percentage of African Americans report a need for substance abuse treatment than whites [17]. Among 
individuals reporting a need to receive treatment for substance use or mental health disorders, whites 
are more likely than African Americans or Latinos to be receiving treatment, and African Americans 
and Latinos are more likely to report unmet need [17]. Additionally, Latinos report less satisfaction 
with all forms of substance use treatment and mental health care than Whites and African Americans 
[17].  
Opiate replacement therapy is a widely used, effective treatment modality for opiate dependence. 
The most readily available form of opiate replacement therapy in the US is methadone maintenance 
therapy (MMT), which has been used to treat chronic heroin addiction for nearly 40 years [20,21]. 
Despite the demonstrated efficacy of MMT in reducing heroin usage [22,23], HIV risk behaviors[24] 
and transmission [25], overdose deaths [26], general mortality [27], and criminal behavior [28,29], 
MMT remains a treatment option that many opiate-dependent individuals do not utilize [20,30]. In a 
study of 28,000 IDUs accessing treatment in Massachusetts, Lundgren et al. found that Latinos and 
African  Americans  were  more  likely  than  whites  to  use  detoxification-only  treatment  for  drug 
addiction, a treatment modality that is generally cheaper and less effective [31,32] than MMT [33]. In 
this same study, African Americans were half as likely as whites to use this effective treatment [33].  
Many  treatment-seeking  IDUs  report  not  being  able  to  enter  treatment  for  reasons  such  as 
unavailability of treatment slots, prohibitively expensive costs or strict admission criteria [34,35]. But 
in addition to factors like cost and availability of treatment, the knowledge, attitudes and beliefs of 
drug users may influence whether and how often different groups access substance use treatment and 
what  types  of  treatment  they  utilize.  Misconceptions  about  methadone  and  ambivalence  toward 
methadone  treatment  have  been  well  documented  [36,37].
 In  qualitative  studies,  opiate-dependent 
IDUs, particularly those not in treatment, generally report negative attitudes toward methadone [35,38]. 
Perceived negative side-effects of methadone, a dislike for the rigid requirements demanded by MMT 
and fear of withdrawal from methadone upon incarceration or involuntary discharge are also reported 
by  opiate-dependent  individuals  as  reasons  for  not  entering MMT  [35]. Common negative beliefs 
about methadone include the views that it is harmful to teeth and bones, that it is more damaging to 
health than heroin, and that withdrawing from methadone is nearly impossible [30]. Negative attitudes 
toward methadone can lead many patients to leave MMT programs prematurely [30], which can result 
in relapse to heroin use and a return to behaviors that put individuals at high risk for drug-related 
morbidity and mortality [22-25,27-29]. Among Latino IDUs in Philadelphia, Porter found that even 
though many individuals reported that MMT was beneficial in controlling their addiction, aspects of 
MMT programs, such as having to attend clinics daily and lack of adequate or culturally appropriate 
counseling services, were significant barriers to remaining in long-term treatment [39]. Even when 
minority  IDUs  enter  treatment,  many  do  not  complete  their  treatment  episodes.  In  her  qualitative 
research with out-of-treatment Latino IDUs, Porter also found that 2/3 of out-of-treatment Latino IDUs Int. J. Environ. Res. Public Health 2009, 6                 
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had dropped out of at least one treatment program because they either did not like the program or were 
asked to leave due to a violation of program rules [39].  
Given  that  methadone  has  been  shown  to  be  an  effective  treatment  for  opiate  addiction  and 
prevention strategy for the transmission of HIV and other infectious diseases, understanding why many 
IDUs do not currently participate in MMT merits further investigation. The diversity in populations of 
injection drug users makes understanding different racial and ethnic groups’ views about MMT crucial 
to designing interventions that are culturally appropriate, effective and function to improve access to 
opiate  addiction  treatment  and  to  prevent  IDU-related  morbidity  and  mortality.  In  this  article,  we 
present data from surveys administered to out-of-treatment minority IDUs in Providence, RI.  
 
2. Subjects and Methods 
 
To collect data about perceptions of MMT among minority IDUs, between January 2007 and April 
2008 we administered a brief survey to consenting out-of-treatment minority IDUs in Providence, RI. 
The survey was adapted from an instrument developed by Stancliff et al. to measure beliefs about 
methadone in an urban methadone clinic [30]. IDUs were recruited through participation at a free 
community HIV testing site and through street outreach by the city’s only needle exchange program, 
which is funded by the Department of Health and run by a local AIDS service organization. Individuals 
coming to MAP Outreach, a South Providence HIV testing and outreach site that provides evidence-
based prevention interventions primarily to African American and Latino substance users, were offered 
the survey if they indicated IDU as a primary risk factor while being tested for HIV. AIDS Care Ocean 
State (ACOS) needle exchange outreach workers offered the survey to individuals they encountered 
while doing street-based syringe exchange with IDUs. The survey contained specific questions relating 
to constructs surrounding attitudes, beliefs and practices regarding methadone treatment. Interviews 
took approximately 15 minutes and all participants received a $10 food voucher for their participation.  
 
2.1. Study Sample 
 
We chose to target our recruitment efforts for this study on African American and Latino IDUs (the 
two most prevalent racial and ethnic minority populations in greater Providence) as insufficient data 
exists in Rhode Island about barriers and facilitators minority IDUs encounter in accessing MMT. For 
example, nearly 80% of all MMT patients in the state are Caucasian, while the total number of IDUs is 
much  more  heterogeneous.  Our  total  sample  consisted  of  53  participants.  While  no  statistical 
information was compiled regarding refusal rates, nearly everyone approached agreed to participate in 
the survey. The high acceptance rate was largely a function of the trusting relationships that clients had 
with the HIV testing agency and the street based needle exchange program. Homogenous sampling 
techniques were used to recruit IDUs to ensure that individuals were as similar as possible with respect 
to specific demographic characteristics.  
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2.2. Data Analysis 
 
The  prevalence  of  specific  knowledge,  attitudes  and  practices  were  determined.  Participant 
demographics were tabulated and binomial probability analyses were performed to examine differences 
regarding specific survey responses. All survey responses were transformed into categorical variables 
and exact hypothesis testing was used to determine statistical significance between responses. All tests 
were two-sided and p-values < 0.05 were considered statistically significant. All statistical analyses 
were performed using STATA version 9. The Institutional Review Board of The Miriam Hospital 
approved the study protocol. 
 
3. Results 
3.1. Participant Characteristics 
 
In the sample of 53 respondents, 11 (21%) were female and 41 (79%) were male, with an average 
age of 40 years. Fourteen respondents (26%) identified as non-Hispanic black and 39 (74%) identified 
as Hispanic. Among respondents identifying as Hispanic, the majority (79%) reported being of Puerto 
Rican  origin.  Thirty-two  respondents  (60%)  reported  past  experience  with  methadone  therapy. 
Participant characteristics are detailed in Table 1. 
Table 1. Participant characteristics. 
   Total, n (%)  53 (100%) 
Age      
   20 - 29 y  6 (12%) 
   30 - 39 y  19 (37%) 
   40 - 49 y  21 (41%) 
   50 - 59 y  5 (10%) 
Gender    
   Female  11 (21%) 
   Male  41 (79%) 
Race/Ethnicity    
   Black, non-Hispanic  14 (26%) 
   Hispanic (any race)  39 (74%) 
Place of Birth    
   USA  14 (29%) 
   Puerto Rico  31 (63%) 
   Other or Multiple  4 (8%) 
Drug(s) of Choice*    
   Heroin  34 (64%) 
   Cocaine/Crack  5 (9%) 
   Heroin and Cocaine/Crack  14 (26%) 
Utilize Syringe Exchange Programs    
   Yes  27 (51%) 
   No  26 (49%) Int. J. Environ. Res. Public Health 2009, 6                 
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Table 1. Cont. 
Source of Needles**     
   Individuals  13 (27%) 
   Syringe Exchange  20 (41%) 
   Pharmacy  20 (41%) 
   Other  4 (8%) 
Past Methadone Treatment    
   Yes  32 (60%) 
   No  21 (40%) 
*All participants indicated heroin use, but survey responses reflect their primary drug of choice. 
**Percents do not add up to 100 since participants could indicate more than one response. 
 
3.2. Knowledge, Attitudes and Beliefs  
 
Respondents  generally expressed negative attitudes  toward methadone. Most respondents  (73%, 
p<0.01)  believed  or  were  uncertain  that  methadone  was  bad  for  a  person’s  health.  Seventy-seven 
percent  of  respondents  (p<0.01)  believed  that  people  should  attempt  to  discontinue  methadone 
treatment. Most respondents believed that methadone programs are too expensive (70%, p=0.01) and 
also that coming to a methadone clinic for treatment makes life difficult (72%, p<0.01). 
Sixty-six percent of respondents (p=0.03) believed that being on methadone means that a person is 
not abstinent from drugs, and 70% (p=0.01) perceived that people in recovery look down upon people 
on  methadone  therapy.  Despite  generally  negative  attitudes  toward  methadone  therapy,  62%  of 
respondents (p=0.01) believed that it would helpful for opiate users to receive methadone at doctors’ 
offices. Participant responses are detailed in Table 2. 
 
Table 2. Attitudes and Beliefs. 
Methadone is bad for a person's health.        
   Agree or Don't Know  38  (73%)    
   Disagree  14  (27%)  <0.01 
People should try to get off methadone.        
   Agree  41  (77%)    
   Disagree or Don't Know  12  (23%)  <0.01 
Methadone treatment prevents HIV and/or HCV.        
   Agree  20  (38%)    
   Disagree or Don't Know  33  (62%)  0.09 
Being on methadone means a person isn't abstinent from drugs.        
   Agree  35  (66%)    
   Disagree or Don't Know  18  (34%)  0.03 
People in recovery look down on those on methadone.        
   Agree  37  (70%)    
   Disagree or Don't Know  16  (30%)  0.01 Int. J. Environ. Res. Public Health 2009, 6                 
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Table 2. Cont. 
Coming to methadone clinic makes life difficult.        
   Agree  38  (72%)    
   Disagree or Don't Know  15  (28%)  <0.01 
Methadone programs are too expensive.        
   Agree  37  (70%)    
   Disagree or Don't Know  16  (30%)  0.01 
People would be helped if methadone were offered in doctors' offices.        
   Agree  33  (62%)    
   Disagree or Don't Know  20  (38%)  0.01 
Being on methadone brings shame on a person's family.        
   Agree  18  (37%)    
   Disagree or Don't Know  31  (63%)  0.09 
There should be family counseling at methadone clinics.        
   Agree  42  (86%)    
   Disagree or Don't Know  7  (14%)  <0.01 
Clinics don't understand different cultures or minority issues.        
   Agree  28  (58%)    
   Disagree or Don't Know   20  (42%)  0.32 
 
4. Discussion 
 
Potential barriers to treatment identified by this study include beliefs about the negative effects of 
methadone on health, the legitimacy of MMT as a drug treatment modality, and the cost of MMT. 
These  findings  are  consistent  with  recent  research  in  Baltimore  among  a  predominantly  African-
American population of IDUs that has identified similar barriers to treatment entry as well as generally 
negative  perceptions  of  methadone,  particularly  among  out-of-treatment  individuals  [35,38].  A 
potentially important barrier to either initiating or continuing MMT is the belief that methadone is 
harder to withdraw from than heroin, which was emphasized in writing by several study participants. 
One participant wrote that methadone “makes you sicker when you stop” and another commented, 
“After getting out of methadone, it was worse than the drug habit. I had to use heroin again and then go 
to detox”.  
Though  not  statistically  significant,  some  differences  were  found  in  the  responses  of  African 
Americans and Latinos, with more Latinos believing that methadone brings shame on a person’s family 
and also that people at methadone clinics do not understand different cultures or minority issues. These 
differences  highlight  the  need  to  develop  a  better  understanding  of  the  obstacles  encountered  by 
Latinos,  which  may  include  language  and  cultural  barriers  to  accessing  treatment.  An  important 
component of providing appropriate substance use and other health-related treatment services to Latino 
communities is understanding cultural context and recognizing barriers to enrollment and retention as 
well as delivering or linking to comprehensive services [40].  
It is interesting to note that in the neighboring state of Massachusetts, Reynoso-Vallejo et al. found 
that Puerto Rican men were more likely than other male Latino IDUs to utilize methadone maintenance Int. J. Environ. Res. Public Health 2009, 6                 
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[41].  Yet  negative  attitudes  persist  among  Puerto  Rican  IDUs  included  in  our  study.  There  is 
significant variability even within racial and ethnic sub-groups, and to develop a full understanding of 
the treatment needs of specific populations of IDUs, the effects of specific factors like geographic 
location, place of birth and degree of acculturation must be examined [5,6]. 
 
Limitations 
 
Limitations  of  this  study  include  the  small  sample  size  and  potential  for  bias  in  the  sampling 
procedure, as the potential for self selection was present among individuals accessing HIV testing or 
needle exchange services. Participants entered the study through either a syringe exchange or HIV 
testing program and may not be representative of the general IDU population in Providence. Compared 
to local demographics, Puerto Ricans are overrepresented in the study population. However, anecdotal 
information from outreach workers suggests that Puerto Ricans are over-represented in the Providence 
IDU population, which is consistent with national findings about substance use among Latino sub-
populations[5,7]. It is possible that social desirability bias also affected survey responses. Due to the 
above limitations, the results of this study may not be generalizable to specific groups in Providence or 
other regions of the US and should be interpreted with caution. Additionally, even though this study 
focuses exclusively on MMT, efforts should be made to understand barriers to enrolling minority IDUs 
in buprenorphine maintenance treatment, another effective form of opiate replacement therapy. 
 
5. Conclusion 
 
Our study highlights the need for targeted education about MMT for out-of-treatment minority drug 
users, including education in Spanish to effectively reach the underserved population of Latino IDUs. 
More  research  is  needed  to  understand  specific  cultural  attitudes  toward  addiction  and  addiction 
treatment in many Latino and African-American communities. Further research should address the 
questions of how misconceptions about methadone can be dispelled and how treatment providers can 
become more responsive to minority, particularly Latino, populations. It addition, MMT clinics should 
be more engaged in understanding and addressing the specific needs of minority IDUs that might be 
uncomfortable or unable to communicate with clinic staff.  
The gravity of the negative social and health consequences often accompanying opiate addiction, 
including HIV and HCV infection, demands a stronger response from researchers and drug treatment 
providers to more effectively enroll minority IDUs in opiate addiction treatment. Developing a better 
understanding of minority attitudes toward MMT and using this understanding to reduce racial and 
ethnic disparities in MMT utilization has the potential to mitigate inequalities in opiate addiction and 
drug-related morbidity and mortality in racial and ethnic minority populations.  
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